Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
AVIR Insider Transactions (Form 4)
68
19 Form 4 filings on record, the earliest from Dec 12, 2024, newest first.
Atea Pharmaceuticals, Inc. (AVIR) had 8 insider filings in the last 90 days, with the most recent on 2026-06-23. The full record for AVIR runs to 19 Form 4 filings, the earliest from 2024-12-12. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying AVIR stock?
No insider purchases of AVIR were filed in the last 90 days. 2 purchases are on record for this company.
How many insiders are selling AVIR stock?
No insider sales of AVIR were filed in the last 90 days. 1 sale is on record for this company.
Where can I see AVIR SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page tracks AVIR Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow AVIR insider buys?
Create a free InsiderAlpha account and press Watch on this page to add AVIR to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.